TY - JOUR
T1 - Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders
AU - On-behalf of the Guthy-Jackson Foundation NMO International Clinical Consortium
AU - Abboud, Hesham
AU - Salazar-Camelo, Andrea
AU - George, Naveen
AU - Planchon, Sarah M.
AU - Matiello, Marcelo
AU - Mealy, Maureen A.
AU - Goodman, Andrew
AU - Alroughani, Raed
AU - Altintas, Ayse
AU - Apiwattanakul, Metha
AU - Asgari, Nasrin
AU - Paolilo, Renata Barbosa
AU - Bennett, Jeffrey
AU - Bichuetti, Denis Bernardi
AU - Blaschke, Terrence F.
AU - Boyko, Alexey
AU - Broadley, Simon
AU - Carnero Contentti, Edgar
AU - Cohen, Jeffrey A.
AU - Delgado-Garcia, Guillermo
AU - Basuroski, Irena Dujmovic
AU - Flores-Rivera, Jose
AU - Fujihara, Kazuo
AU - Havla, Joachim
AU - Hellwig, Kerstin
AU - Hor, Jyh Yung
AU - Huda, Saif
AU - Iorio, Raffaele
AU - Jarius, Sven
AU - Kimbrough, Dorlan
AU - Kister, Ilya
AU - Kleiter, Ingo
AU - Kissani, Najib
AU - Lana-Peixoto, Marco
AU - Leite, Maria Isabel
AU - Levy, Michael
AU - Maiga, Youssoufa
AU - Mao-Draayer, Yang
AU - Mariotto, Sara
AU - Melamed, Esther
AU - Neubrand, Veronika E.
AU - Oreja-Guevara, Celia
AU - Palace, Jacqueline
AU - Pröbstel, Anne Katrin
AU - Qian, Peiqing
AU - Quan, Chao
AU - Riley, Claire
AU - Ringelstein, Marius
AU - Sa, Maria Jose
AU - Wingerchuk, Dean
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2022/4
Y1 - 2022/4
N2 - Neuromyelitis optica spectrum disorders (NMOSD) are a group of autoimmune inflammatory conditions that primarily target the optic nerves, spinal cord, brainstem, and occasionally the cerebrum. NMOSD is characterized by recurrent attacks of visual, motor, and/or sensory dysfunction that often result in severe neurological deficits. In recent years, there has been a significant progress in relapse treatment and prevention but the residual disability per attack remains high. Although symptomatic and restorative research has been limited in NMOSD, some therapeutic approaches can be inferred from published case series and evidence from multiple sclerosis literature. In this review, we will discuss established and emerging therapeutic options for symptomatic treatment and restoration of function in NMOSD. We highlight NMOSD-specific considerations and identify potential areas for future research. The review covers pharmacologic, non-pharmacologic, and neuromodulatory approaches to neuropathic pain, tonic spasms, muscle tone abnormalities, sphincter dysfunction, motor and visual impairment, fatigue, sleep disorders, and neuropsychological symptoms. In addition, we briefly discuss remyelinating agents and mesenchymal stem cell transplantation in NMOSD.
AB - Neuromyelitis optica spectrum disorders (NMOSD) are a group of autoimmune inflammatory conditions that primarily target the optic nerves, spinal cord, brainstem, and occasionally the cerebrum. NMOSD is characterized by recurrent attacks of visual, motor, and/or sensory dysfunction that often result in severe neurological deficits. In recent years, there has been a significant progress in relapse treatment and prevention but the residual disability per attack remains high. Although symptomatic and restorative research has been limited in NMOSD, some therapeutic approaches can be inferred from published case series and evidence from multiple sclerosis literature. In this review, we will discuss established and emerging therapeutic options for symptomatic treatment and restoration of function in NMOSD. We highlight NMOSD-specific considerations and identify potential areas for future research. The review covers pharmacologic, non-pharmacologic, and neuromodulatory approaches to neuropathic pain, tonic spasms, muscle tone abnormalities, sphincter dysfunction, motor and visual impairment, fatigue, sleep disorders, and neuropsychological symptoms. In addition, we briefly discuss remyelinating agents and mesenchymal stem cell transplantation in NMOSD.
KW - Mesenchymal stem cells
KW - NMO
KW - NMOSD
KW - Neuromyelitis optica
KW - Neuropathic pain
KW - Remyelination
KW - Symptomatic
KW - Tonic spasms
UR - http://www.scopus.com/inward/record.url?scp=85114427931&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114427931&partnerID=8YFLogxK
U2 - 10.1007/s00415-021-10783-4
DO - 10.1007/s00415-021-10783-4
M3 - Review article
C2 - 34482456
AN - SCOPUS:85114427931
SN - 0340-5354
VL - 269
SP - 1786
EP - 1801
JO - Journal of Neurology
JF - Journal of Neurology
IS - 4
ER -